A London company that provides AI software to the biopharmaceutical and healthcare industry has appointed Simon Coulthard as itsnew CFO.
PangaeaData has also appointedProfessorMark Musen,Dr.Rick Sax andOzgurTuncer to its Scientific Advisory Board (SAB).
Coulthardjoins Pangaea fromCongenica,a digital health company spun out of theWellcomeSanger Institute, where he was instrumental inarecent $50m Series C funding round.
The company says hewill leverage a decade of international experience in software development and the recent global growth inCongenica’sdigital health platform to accelerateexpansion into Pangaea’s key strategic markets within the US healthcare and pharmaceutical industry.
/biotech-behind-covid-19-tracking-to-float-in-london/
Professor Musen is a professor of Biomedical Informatics and Director of the StanfordCentre for Biomedical Informatics Research at Stanford University. He chaired the Health Informatics andModelingTopic Advisory Group for the World Health Organisation’s revision of the International Classification of Diseases, and is also principal investigatorof the Center for Expanded Data Annotation and Retrieval (CEDAR).
Dr Saxwaspreviously a Senior Vice President at IQVIA and formerly a Clinical Vice-Presidentat AstraZeneca.He has established himself as an expert on drug research and development,advising UK and US venture capitalists on the risk perspective of pharmaceutical investments and asset development strategies.
TuncerisGlobal Vice President, Financial Institutions at IQVIA and Investment Partner at Ascension Life Sciences Fund.Headvises senior decision makers in the biopharmaceutical industry across Europe, USA and Middle East, focusing on M&A, valuationsand portfolio management.
“I am delighted to join the team at Pangaea. The work they have been doing using AI to extract vital information from doctors’ notes, discharge summaries and other sources is revolutionising how the pharmaceutical industry finds cohorts for drug trials, takinga process that usually takes several months down to a few weeks,” said Coulthard.
“The connections they have already established with key players in the pharmaceutical market clearly demonstrate their unique offering.
“I look forward to working with the leadership team to furtherscale the business and achieve increasing recurring revenues as their platform is used for multiple applications across an enterprise.”
/can-biotech-halt-disease-which-has-led-to-slaughter-of-300000-cattle/
Dr Vibhor Gupta,founder and CEO of Pangaea,added:“The additions of Mr Simon Coulthard, Professor Musen, Dr Rick Sax and Mr Ozgur Tuncer to our team will have a significant impact on the growth of our company. Their combined industry experiences of more than 60 years and global network are unparalleled.
“Ata time when our novel AI is being embedded within the core life sciences infrastructure, their knowledge will be invaluable to help us scale and expand in new markets.”


